Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib
J Dermatolog Treat. 2024 Dec;35(1):2304630. doi: 10.1080/09546634.2024.2304630. Epub 2024 Jan 19.NO ABSTRACTPMID:38240097 | DOI:10.1080/09546634.2024.2304630 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - January 19, 2024 Category: Dermatology Authors: Francisco Javier De la Torre-Gomar Juan Pablo Velasco-Amador Álvaro Prados-Carmona Ricardo Ruiz-Villaverde Source Type: research
Baricitinib for the Treatment of Alopecia Areata in Adults: Real-World Analysis of 36 Patients.
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - January 19, 2024 Category: Dermatology Authors: C. Moreno-V ílchez, M. Bonfill-Ortí, A. Bauer-Alonso, J. Notario., I. Figueras-Nart Source Type: research
Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients
This study aims to assess baricitinib ’s real-world efficacy and safety in AA. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - January 19, 2024 Category: Dermatology Authors: Carlos Moreno-V ílchez, Montserrat Bonfill-Ortí, Andrea Bauer-Alonso, Jaime Notario, Ignasi Figueras-Nart Tags: Research letter Source Type: research
Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata
ConclusionThis study provided compelling genetic evidence supporting a causative association between hypothyroidism and alopecia areata, which could potentially inform the development of more efficacious treatment strategies for patients afflicted by alopecia areata. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - January 16, 2024 Category: Endocrinology Source Type: research
Risk of Alopecia Areata After COVID-19
This cohort study examines the incidence, prevalence, and risk of alopecia areata after COVID-19. (Source: JAMA Dermatology)
Source: JAMA Dermatology - January 10, 2024 Category: Dermatology Source Type: research
Noval advance of histone modification in inflammatory skin diseases and related treatment methods
Inflammatory skin diseases are a group of diseases caused by the disruption of skin tissue due to immune system disorders. Histone modification plays a pivotal role in the pathogenesis and treatment of chronic inflammatory skin diseases, encompassing a wide range of conditions, including psoriasis, atopic dermatitis, lupus, systemic sclerosis, contact dermatitis, lichen planus, and alopecia areata. Analyzing histone modification as a significant epigenetic regulatory approach holds great promise for advancing our understanding and managing these complex disorders. Additionally, therapeutic interventions targeting histone m...
Source: Frontiers in Immunology - January 3, 2024 Category: Allergy & Immunology Source Type: research
Topical sodium valproate-loaded nanospanlastics versus conventional topical steroid therapy in alopecia areata: a randomized controlled study
ConclusionBoth topical SV and steroids are of comparable modest efficacy. Thus, further evaluation of SV is due in combination with intralesional steroids and other anti-inflammatory treatment modalities, together with developing individualized approaches based on baseline beta-catenin level.ClinicalTrials.gov IdentifierNCT05017454,https://clinicaltrials.gov/ct2/show/NCT05017454. (Source: Archives of Dermatological Research)
Source: Archives of Dermatological Research - January 3, 2024 Category: Dermatology Source Type: research
Status of research on the development and regeneration of hair follicles
Int J Med Sci. 2024 Jan 1;21(1):80-94. doi: 10.7150/ijms.88508. eCollection 2024.ABSTRACTHair loss, or alopecia, is a prevalent condition in modern society that imposes substantial mental and psychological burden on individuals. The types of hair loss, include androgenetic alopecia, alopecia areata, and telogen effluvium; of them, androgenetic alopecia is the most common condition. Traditional treatment modalities mainly involve medical options, such as minoxidil, finasteride and surgical interventions, such as hair transplantation. However, these treatments still have many limitations. Therefore, exploring the pathogenesi...
Source: International Journal of Medical Sciences - January 2, 2024 Category: Biomedical Science Authors: Dan Liu Qi Xu Xiangyuan Meng Xiaomei Liu Jinyu Liu Source Type: research
Corneal transplant rejection and alopecia areata universalis in a patient with severe atopic dermatitis on dupilumab
Actas Dermosifiliogr. 2023 Dec 28:S0001-7310(23)01003-7. doi: 10.1016/j.ad.2023.02.039. Online ahead of print.NO ABSTRACTPMID:38159837 | DOI:10.1016/j.ad.2023.02.039 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - December 30, 2023 Category: Dermatology Authors: T Lopez-Bernala M Mazaira Fern ándeza I Vargas-Machuca Salidoa B Araneguia Source Type: research
Corneal transplant rejection and alopecia areata universalis in a patient with severe atopic dermatitis on dupilumab
Actas Dermosifiliogr. 2023 Dec 28:S0001-7310(23)01003-7. doi: 10.1016/j.ad.2023.02.039. Online ahead of print.NO ABSTRACTPMID:38159837 | DOI:10.1016/j.ad.2023.02.039 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - December 30, 2023 Category: Dermatology Authors: T Lopez-Bernala M Mazaira Fern ándeza I Vargas-Machuca Salidoa B Araneguia Source Type: research
Corneal transplant rejection and alopecia areata universalis in a patient with severe atopic dermatitis on dupilumab
Actas Dermosifiliogr. 2023 Dec 28:S0001-7310(23)01003-7. doi: 10.1016/j.ad.2023.02.039. Online ahead of print.NO ABSTRACTPMID:38159837 | DOI:10.1016/j.ad.2023.02.039 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - December 30, 2023 Category: Dermatology Authors: T Lopez-Bernala M Mazaira Fern ándeza I Vargas-Machuca Salidoa B Araneguia Source Type: research
Corneal transplant rejection and alopecia areata universalis in a patient with severe atopic dermatitis on dupilumab
Actas Dermosifiliogr. 2023 Dec 28:S0001-7310(23)01003-7. doi: 10.1016/j.ad.2023.02.039. Online ahead of print.NO ABSTRACTPMID:38159837 | DOI:10.1016/j.ad.2023.02.039 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - December 30, 2023 Category: Dermatology Authors: T Lopez-Bernala M Mazaira Fern ándeza I Vargas-Machuca Salidoa B Araneguia Source Type: research
Potential Indications of Dupilumab in Th-2 Inflammatory Disease
Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.ABSTRACTDupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in...
Source: Reviews on Recent Clinical Trials - December 23, 2023 Category: Cancer & Oncology Authors: Proietti Ilaria Skroza Nevena Tolino Ersilia Bernardini Nicoletta Federica Trovato Marco Di Fraia Dybala Agniezska Potenza Concetta Source Type: research
